Skip to main content

GLP-1 Agonists in Psoriatic Arthritis

Dr. Peter Nash | ACR 2026

Transcription

Hi everyone, Peter Nash reporting from ACR Convergence Orlando 2026. And even though you're sick of hearing about GLP-1 agonists, at every meeting now we have talks about it. Jack just did a whole month on managing obesity and psoriatic arthritis. At this meeting there were 28 abstracts on GLP-1 agonists.

I'm going to talk about the five in PsA, but they had GLP-1s in interstitial lung disease, giant cell arteritis, SLE, fracture reduction, joint replacement rates, malignancy, cardiovascular outcomes, the REDEFINE trial that was just published in the New England Journal of Medicine with the retatrutide, which is a triple receptor blocker — not only GLP-1 and GIP but also glucagon — studies in sarcoidosis, and study in reduction of VTE risk.

So in PsA, obesity and metabolic syndrome is a major issue — we all know this. And these studies that they presented at this meeting are usually people who have BMIs either over 30, which is the FDA criteria for getting GLP-1 agonists, or they have a BMI between 25 and 27 but they have one obesity comorbidity like hyperglycemia or hypertension.

So bottom line is that the number of patients with PsA with metabolic syndrome is over 50%; general population about 20%. And most of the patients met the criteria to get a GLP-1, but very few patients were actually taking it.

And Lee did a beautiful plenary where she showed nicely: if you're overweight, you're more likely to get PsA. If you're overweight, you're less likely to get MDA. You're less likely to respond to treatment. And if you lose weight — say a 10% reduction, for example, that the GLP-1s can do — you get a six times higher rate of getting MDA.

She talked very much about disease activity. Everyone knows about the TOGETHER study, where the one-year data was presented here comparing tirzepatide with an IL-17 inhibitor and how it was superior. What was interesting is that the line separated — the superiority came up by week four — before they even had a chance to lose significant amounts of weight. So these drugs have an anti-inflammatory effect, and we know that obesity drives IL-6, TNF, and leptin, and that's not unusual. So you get improvement in fatigue, in function, CRP comes down, as well as the metabolic things like weight, blood pressure, triglycerides, and HDL improves.

So the bottom line from all these studies is: think about triple therapy. We should be doing BMI and we should be assessing cardiovascular risk. Please do CT calcium scores in those patients who are at risk. Over 100 needs a cardiologist. Under 100, they may not even need a statin.

And please start the first script. If you send them back to the GP, they think they've been to the fancy specialist but didn't think it was important enough to start — "why should I do it?" You need to start the first script and ask the GP to supervise the uptitration of the dose over time. These patients need exercise or they lose muscle mass. Make sure they tell any anesthetist they're on them because of gastroparesis risk for an endoscopy or surgery. And the side effects are very uncommon compared to the benefits in this patient population.

Be aware: fast weight loss is not the way to go. Slow weight loss is the way to go. There's been a couple of cases of mesenteric thrombosis in patients associated with losing weight too quickly.

Peter Nash signing off. RheumNow, ACR Convergence Orlando 2026.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×